International Journal of COPD (Sep 2017)

A pilot clinical trial to determine the safety and efficacy of aerosolized hyaluronan as a treatment for COPD

  • Cantor J,
  • Ma S,
  • Turino G

Journal volume & issue
Vol. Volume 12
pp. 2747 – 2752

Abstract

Read online

Jerome Cantor,1 Shuren Ma,2 Gerard Turino2 1Department of Pharmaceutical Sciences, St John’s University, 2Department of Medicine, St Luke’s Mount Sinai Hospital Center, New York, NY, USA Abstract: A novel therapy for COPD involving the use of aerosolized hyaluronan (HA) was tested on a small cohort of COPD patients to determine both its safety and efficacy in reducing levels of desmosine and isodesmosine (DID), biomarkers for elastin degradation. In a 2-week, randomized, double-blind trial, 8 patients receiving 150 kDa HA (mean molecular weight) and 3 others given placebo did not show significant adverse effects with regard to spirometry, electrocardiograms, and hematological indices. Furthermore, measurements of DID in plasma from HA-treated patients indicated a progressive decrease over a 3-week period following initiation of treatment (r=−0.98; p=0.02), whereas patients receiving placebo showed no reduction in DID (r=−0.70; p=0.30). Measurements of sputum in the HA-treated group also revealed a progressive decrease in DID (r=−0.97; p=0.03), but this finding was limited by the absence of similar measurements in the placebo group. Nevertheless, the results of this small, pilot study support a longer-term trial of HA in a larger population of COPD patients. Keywords: hyaluronan, COPD, desmosine, elastin

Keywords